G0418 HCPCS Prostate Biopsy Reimbursement | OpenPayer

Summary & Overview

HCPCS G0418: Prostate Needle Biopsy Surgical Pathology, 41-60 Specimens

HCPCS Level II code G0418 designates surgical pathology for prostate needle biopsy when 41–60 tissue specimens are submitted for gross and microscopic examination. This code captures complex pathology work associated with high-volume prostate sampling and is relevant to urology, pathology laboratories, and outpatient surgical centers nationwide. Proper use ensures clinical documentation aligns with specimen counts and supports appropriate billing for extensive pathologic evaluation.

Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise interpretation of what G0418 represents clinically, the typical settings where the service is performed, and what payers commonly cover in this service area. The publication summarizes benchmarking metrics, common billing modifiers, and payer coverage considerations where available, and provides context on when this code is used relative to prostate biopsy procedures.

The report is intended for billing managers, pathologists, urologists, and compliance officers seeking clarity on coding, expected sites of service, and payer coverage implications. Data not available in the input is noted where applicable.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareG0418HCPCS Level IIsurgical pathologyprostate biopsypathology billinglaboratory servicesoutpatient surgeryspecimen counthistopathology

Billing Code Overview

HCPCS Level II code G0418 describes surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens. This service involves pathologist examination of prostate needle biopsy specimens taken to evaluate for malignancy or other histopathologic findings.

Service type: Surgical pathology (gross and microscopic examination)
Typical site of service: Pathology laboratory or hospital outpatient pathology department

Clinical & Coding Specifications

Clinical Context

A typical patient is a 65-year-old man referred to urology for evaluation of elevated prostate-specific antigen (PSA) or an abnormal digital rectal exam. After shared decision-making, a transrectal or transperineal prostate needle biopsy is performed in an ambulatory surgery center or outpatient clinic under local anesthesia or monitored anesthesia care. The urologist obtains multiple core needle specimens (41–60 specimens in this scenario) from systematic and targeted sampling of prostate sextants, including any MRI/ultrasound fusion-targeted cores. Specimens are placed in separate or labeled containers and sent to the pathology laboratory for surgical pathology gross and microscopic analysis documented under G0418 (surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens). The pathology report includes gross description, microscopic findings, Gleason/ISUP grading if adenocarcinoma is identified, perineural or extraprostatic extension, and comment on tumor volume. Typical payors include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare. The professional component (interpretation) is billed with modifier 26 when reported separately and the technical component (laboratory processing) is billed with modifier TC when appropriate. Typical sites of service are ambulatory surgery center, hospital outpatient department, and independent pathology laboratory when specimens are processed offsite.

Coding Specifications

Modifier	Description	When to Use

HCPCS G9965: Missed Well-Child Visit with Primary Care Provider

HCPCS-G0055-ADVANCING-CARE-HEART-DISEASE-MIPS-VALUE-PATHWAYS

HCPCS G0055: Advancing Care for Heart Disease MIPS Value Pathways

HCPCS-G9581-DOOR-TO-PUNCTURE-TIME-OVER-2-HOURS-ENDOVASCULAR-STROKE

HCPCS G9581: Door-to-Puncture >2 Hours for Endovascular Stroke Treatment

HCPCS-G0064-CERTIFIED-NURSE-MIDWIFE-MIPS-SPECIALTY-SET

HCPCS G0064: Certified Nurse Midwife MIPS Specialty Set

HCPCS-G0046-CLINICAL-FOLLOW-UP-ENDOVASCULAR-STROKE-INTERVENTION-MRS-NOT-ASSESSED-90-DAYS

HCPCS G0046: Clinical Follow-Up After Endovascular Stroke Intervention, mRS Not Assessed at 90 Days

HCPCS-G9847-SYSTEMIC-CANCER-THERAPY-LAST-14-DAYS-LIFE

HCPCS G9847: Systemic Cancer-Directed Therapy in Last 14 Days of Life

HCPCS-G0467-FQHC-ESTABLISHED-PATIENT-VISIT

HCPCS G0467: FQHC Visit for Established Patient, Face-to-Face

HCPCS-G8879-CLINICALLY-NODE-NEGATIVE-INVASIVE-BREAST-CANCER

HCPCS G8879: Clinically Node Negative Invasive Breast Cancer

HCPCS-G8949-DIET-PHYSICAL-ACTIVITY-COUNSELING-REFUSAL

HCPCS G8949: Documentation of Diet and Physical Activity Counseling Refusal

HCPCS-G9758-PATIENT-IN-HOSPICE-MEASURE

HCPCS G9758: Patient in Hospice During Measurement Period

Showing 1–10 of 1996

Taxonomy Code	Specialty	Notes
207P00000X	Urology	Urologists perform prostate biopsy and coordinate specimen submission to pathology.
207K00000X	Pathology	Anatomic/Clinical Pathologists perform gross and microscopic examination and sign out `G0418`.
207RC0000X	Radiology, Diagnostic	Diagnostic radiologists may perform or assist with MRI-ultrasound fusion targeting for biopsy cores.
208D00000X	General Surgery	General surgeons in some settings may perform prostate biopsy procedures.
207PS0012X	Surgical Pathology	Subspecialty pathology providers who may interpret prostate specimens and report specialized findings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`N40.1`	Enlarged prostate with lower urinary tract symptoms	Indicative of prostate enlargement prompting evaluation; may coexist with indications for biopsy when PSA or exam is abnormal.
`N40.0`	Enlarged prostate without lower urinary tract symptoms	Prostate enlargement may be an incidental finding; elevated PSA in this context can lead to biopsy.
`R97.20`	Elevated prostate specific antigen [PSA], unspecified	Common laboratory trigger for prostate biopsy and specimen submission under `G0418`.
`R92.1`	Abnormal findings on diagnostic imaging of prostate	Abnormal prostate imaging (e.g., MRI) often leads to targeted biopsy and pathology evaluation.
`D07.5`	Carcinoma in situ of prostate	High-risk histologic findings on biopsy may be related to this code; pathology assesses presence or absence of malignancy.
`C61`	Malignant neoplasm of prostate	Primary diagnosis when biopsy confirms prostate adenocarcinoma; pathology report establishes diagnosis, grade, and extent.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`55700`	Biopsy, prostate; needle or punch, single or multiple, any approach	Surgical procedure code for obtaining prostate needle biopsy specimens; this clinical procedure generates the specimens examined under `G0418`.
`88305`	Level IV surgical pathology, gross and microscopic examination	Common general CPT code for individual biopsy specimen pathology interpretation; may be used for billing pathologist interpretation when Medicare HCPCS `G0418` is not applicable or for individual specimen-level coding.
`88342`	Immunohistochemistry, per specimen; initial single antibody stain	Ancillary test often performed on prostate biopsy tissue to assist in diagnosis (e.g., basal cell markers) and reported in conjunction with `G0418` findings.
`88313`	Special stains (e.g., histochemical), each stain	Additional tissue stains used selectively on prostate cores to clarify morphology; performed during the pathology workup associated with `G0418`.
`88341`	Immunohistochemistry, per specimen; each additional single antibody stain beyond the first	Additional IHC stains when multiple markers are required to characterize atypical lesions in prostate biopsy specimens examined under `G0418`.

OpenPayer